Osmotica Pharmaceuticals plc to Provide Fourth Quarter and Full Year 2020 Business and Financial Update on March 30, 2021
Rhea-AI Summary
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) announced its fourth quarter and full year 2020 financial results will be released on March 30, 2021, after market close. The company’s executives, including CEO Brian Markison, will host a conference call at 4:30 p.m. ET the same day to discuss the results. Osmotica focuses on developing specialty products for underserved patient populations, with operations in the U.S., Argentina, and Hungary, and subsidiaries including RVL Pharmaceuticals, which supports the product UPNEEQ.
Positive
- Scheduled financial results release may provide insights into company performance.
- Focus on underserved markets could indicate potential for growth.
Negative
- None.
News Market Reaction – OSMT
In the trading session that priced this news, OSMT gained 9.77%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BRIDGEWATER, N.J., March 24, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced that the Company will release its 2020 fourth quarter and full year financial results on Tuesday, March 30, 2021, after the close of the U.S. financial markets.
Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and Andrew Einhorn, Chief Financial Officer, will host a conference call as follows:
| Date | Tuesday, March 30, 2021 |
| Time | 4:30 p.m. ET |
| Toll free (U.S.) | (866) 672-5029 |
| International | (409) 217-8312 |
| Conference ID | 5056728 |
| Webcast (live and replay) | www.osmotica.com under the “Investor & News” section |
About Osmotica Pharmaceuticals plc
Osmotica Pharmaceuticals plc is a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations. RVL Pharmaceuticals, Inc. is the Company’s ophthalmic subsidiary supporting UPNEEQ. Vertical Pharmaceuticals, LLC represents the Company’s diversified branded portfolio and Trigen Laboratories, LLC represents the Company’s non-promoted products, including complex generic formulations.
Osmotica has operations in the United States, Argentina, and Hungary.
Investor and Media Relations for Osmotica Pharmaceuticals plc
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com